Table 2.
Clinical application & clinical trials of CXCL12-CXCR4/CXCR7 signaling axis inhibitors/antagonists in tumors
| Inhibitor/ Antagonist | Company | Target | Cancer | Clinical Trial Number (status) | Trial Phase | Other indications |
|---|---|---|---|---|---|---|
| Clinical application: | ||||||
| AMD3100 | Sanofi Aventis | CXCR4 | — | — | — | MM or non-Hodgkin lymphoma |
| Clinical trials: | ||||||
| AMD3100 (+bortezomib) | Sanofi Aventis | CXCR4 | MM | NCT00903968 (completed) | Phase 1/2 | MM or non-Hodgkin lymphoma |
| AMD3100 (+sorafenib and G-CSF) | Sanofi Aventis | CXCR4 | Relapsed/refractory FLT3-ITD mutant AML | NCT00943943 (completed) | Phase 1 | |
| BKT140 | BioLineRx | CXCR4 | MM | NCT01010880 (completed) | Phase 1 | Non-small cell lung cancer, non-hodgkin lymphoma, and AML |
| BKT140 (+pembrolizumab and chemotherapy) | BioLineRx | CXCR4 | Pancreatic ductal adenocarcinoma | NCT02826486 (completed) | Phase 2 | |
| BKT140 (+cytarabine) | BioLineRx | CXCR4 | Relapsed/refractory AML | NCT01838395 (completed) | Phase 2 | |
| POL6326 (+ eribulin) | Polyphor | CXCR4 | HER2-negative metastatic breast cancer | NCT01837095 (completed) | Phase 1 | Leukemia and MM |
| Ulocuplumab (+ibrutinib) | Bristol-Myers Squibb | CXCR4 | Waldenström macroglobulinemia | NCT03225716 (active, not recruiting) | Phase 1/2 | Hematologic malignancies |
| Ulocuplumab (+lenalidomide and dexamethasone) | Bristol-Myers Squibb | CXCR4 | Relapsed/refractory MM | NCT01359657 (completed) | Phase 1 | |
| NOX-A12 | NOXXON Pharma | CXCL12 | Advanced metastatic colorectal and pancreatic cancer | NCT03168139 (completed) | Phase 1/2 | Chronic lymphocytic leukemia, and brain tumors |